Johann Morelle
LightNews LightNews
banner
johannmorelle.bsky.social
Johann Morelle
@johannmorelle.bsky.social
510 followers 120 following 31 posts
MD, PhD, FASN | Head of the Division of Nephrology at University Hospitals Namur (www.chuuclnamur.be) | Associate Professor of Nephrology | Physician-scientist at de Duve Institute (www.deduveinstitute.be) Special interest in glomerular diseases and TMA
Posts Media Videos Starter Packs
Reposted by Johann Morelle
jeffminerphd.bsky.social
Jeff Miner @jeffminerphd.bsky.social · Jul 31
Thrilled to have this finally published! If you are interested in learning about the collagen IV diseases Gould syndrome and Alport syndrome, add this to your reading list. www.nature.com/articles/s41...
Collagen IV in Gould syndrome and Alport syndrome
Nature Reviews Nephrology - In this Review, the authors focus on the role of collagen IV in Gould syndrome and Alport syndrome. They discuss the molecular and phenotypic similarities and...
www.nature.com
5 10 31
Reposted by Johann Morelle
janewit-thekidgene.bsky.social
Janewit Wongboonsin @janewit-thekidgene.bsky.social · Jul 19
🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025

authors.elsevier.com/a/1lSgWzcYo6...

@andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
authors.elsevier.com
5 9 19
Reposted by Johann Morelle
izabelazakrocka.bsky.social
Izabela Zakrocka @izabelazakrocka.bsky.social · Jun 7
We got it 💪🏻 #ERA25 thank you @rosertorra.bsky.social 👏🏻
2 8
johannmorelle.bsky.social
Johann Morelle @johannmorelle.bsky.social · Jun 6
Thanks for catching up and for attending, Izabela! So happy to have met you in person! 😊
2
Reposted by Johann Morelle
izabelazakrocka.bsky.social
Izabela Zakrocka @izabelazakrocka.bsky.social · Jun 6
Finding novel antigens in membranous nephropathy through mass spectrometry by @johannmorelle.bsky.social #ERA25
1 1 5
Reposted by Johann Morelle
hswapnil.medsky.social
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jun 5
The first #ERA25 simultaneous pub

CONFIDENCE trial of empagliflozin + finerenone in N = 579

Greater reduction in ACR and BP
Note the impressive GFR dip

www.nejm.org/doi/full/10....
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.
4 24 40
Reposted by Johann Morelle
hswapnil.medsky.social
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jun 3
Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees!

@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
award winner list
4 7 31
Reposted by Johann Morelle
ajkd.bsky.social
American Journal of Kidney Diseases @ajkd.bsky.social · May 24
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy

bit.ly/4ccCs4H #OpenAccess

#VisualAbstract
1 3
Reposted by Johann Morelle
ndt-era.bsky.social
NDT @ndt-era.bsky.social · May 15
Complement activation in secondary thrombotic microangiopathies

doi.org/10.1093/ndt/...

👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
3 4
johannmorelle.bsky.social
Johann Morelle @johannmorelle.bsky.social · May 16
Secondary #TMA represent a major unmet medical need.

Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases.

🙏 to outstanding co-authors and the #ERA IWG

@kronbichlerlab.bsky.social
@ndt-era.bsky.social
ndt-era.bsky.social NDT @ndt-era.bsky.social · May 15
Complement activation in secondary thrombotic microangiopathies

doi.org/10.1093/ndt/...

👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
2 5
Reposted by Johann Morelle
erictopol.bsky.social
Eric Topol @erictopol.bsky.social · May 15
Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism"
—the 1st human to undergo custom genome editing
—from decades of NIH funded research
www.nejm.org/doi/full/10....
@nejm.org
www.nejm.org/doi/full/10....
www.nytimes.com/2025/05/15/h...
10 170 600
Reposted by Johann Morelle
hswapnil.medsky.social
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · May 11
Beautiful essay from Rajeev Raghavan in the @nejm.org

Driving Jackson (a dialysis patient to his clinic appointments)

www.nejm.org/doi/full/10....

#NephSky
Driving Jackson | NEJM
When a low-income patient receiving home dialysis misses the bus to the clinic, his nephrologist makes a decision that launches a long-term relationship and brings unexpected meaning into his own life...
www.nejm.org
2 7 11
Reposted by Johann Morelle
asnpublications.bsky.social
ASN Publications @asnpublications.bsky.social · May 7
In an article within the #ASNJASN series, Mechanisms of Kidney Diseases, authors examine the link between gold salts, penicillamine, and mercury and membranous nephropathy, aiming to develop new hypotheses on how these substances may promote immune dysregulation. https://bit.ly/JASN0719
1 2
Reposted by Johann Morelle
hswapnil.medsky.social
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · May 3
The whole story is surreally fascinating

Tim Friede’s YT channel: youtube.com/@timfriede57...

The @cellpress.bsky.social paper: www.cell.com/cell/fulltex...

A BBC story www.bbc.com/news/article...

A universal antivenom would be huge - this seems like a big step
Graphical abstract
1 4 10
Reposted by Johann Morelle
glombandit.bsky.social
Tiff Caza @glombandit.bsky.social · May 3
Some take home messages from an inspiring talk by @nephrorock.bsky.social at @kidneycon.bsky.social !
1 6
Reposted by Johann Morelle
nephroseeker.medsky.social
Cristina Popa @nephroseeker.medsky.social · Apr 29
🔥 Happening tonight #nephjc
3 3
johannmorelle.bsky.social
Johann Morelle @johannmorelle.bsky.social · Apr 29
🔥 Final (pdf) version available online (free):

Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy

@ajkd.bsky.social

➡️ doi.org/10.1053/j.aj...

#OpenAccess

🙏 to all collaborators and sponsors!
1 3 5
Reposted by Johann Morelle
nejm.org
NEJM.org @nejm.org · Apr 23
In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf

#MedSky #CardioSky
A graph showing the least-squares mean changes from baseline (randomization) in the 24-hour average ambulatory systolic blood pressure at 12 weeks.
1 9 14
Reposted by Johann Morelle
hswapnil.medsky.social
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Apr 23
The ASIs have arrived

www.nejm.org/doi/full/10....

Aldosterone synthase inhibitors - first one to finish the phase 3 line

#Lorundrostat #Hypertension
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
www.nejm.org
3 27 37
Reposted by Johann Morelle
erictopol.bsky.social
Eric Topol @erictopol.bsky.social · Apr 24
Why you should know your viral exposure status (i.e CMV) if you're going to undergo immunotherapy for cancer (but almost no one knows)
www.nature.com/articles/s41...
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade - Nature Medicine
Analysis of multiple cohorts of patients with melanoma demonstrates a positive association between cytomegalovirus serostatus and overall survival in patients treated with monotherapy but not combinat...
www.nature.com
5 61 210
Reposted by Johann Morelle
delanaye.bsky.social
Pierre Delanaye @delanaye.bsky.social · Apr 21
EKFC equation to estimate GFR from creatinine and cystatin C, you freely use this link

ekfccalculator.pages.dev
ekfccalculator.pages.dev
1
Reposted by Johann Morelle
edgarvlermamd.bsky.social
Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · Apr 15
Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial
#Nephpearls #NKFClinicals 🇺🇸 #NephSky

📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
1 5 5
Reposted by Johann Morelle
edgarvlermamd.bsky.social
Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · Apr 11
DUPLEX Posthoc: Antiproteinuric and nephroprotective benefits of Sparsentan in patients with FSGS
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
1 1 2
Reposted by Johann Morelle
edgarvlermamd.bsky.social
Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · Apr 11
PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS
#Nephpearls #NKFClinicals #NephSky
2 4
Reposted by Johann Morelle
edgarvlermamd.bsky.social
Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · Apr 11
Sparsentan (DEARA) and FSGS
#Nephpearls #NKFClinicals #NephSky
2 7